Literature DB >> 25973239

Study on risk factors and phenotypes of acute exacerbations of chronic obstructive pulmonary disease in Guangzhou, China-design and baseline characteristics.

Yumin Zhou1, Piet L B Bruijnzeel1, Christopher McCrae1, Jinping Zheng1, Ulf Nihlen1, Rong Zhou1, Marleen Van Geest1, Anna Nilsson1, Sinela Hadzovic1, Monika Huhn1, Ziad Taib1, Yi Gu1, Jiaxing Xie1, Pixin Ran1, Rongchang Chen1, Nanshan Zhong1.   

Abstract

BACKGROUND: To describe a study design that focuses on risk factors and patterns of chronic obstructive pulmonary disease (COPD) exacerbations.
METHODS: A 2-year, single centre, observational study was conducted in Guangzhou in China. The study enrolled 318 subjects with COPD aged 40-79 years, stratified into different but equally sized groups according to global initiative for chronic obstructive lung disease (GOLD) stage (including Stage 0) and 86 lung healthy controls. An assessment each year was scheduled including questionnaires, lung function testing, Chest X-ray and blood collection. A sub-group, called sub-group X, consisting of 203 subjects with COPD and 51 lung healthy controls, was selected to answer a symptom questionnaire daily (EXACT-PRO) via a BlackBerry Personal Digital Assistant (PDA) device. Upon an alert that indicated a change in daily symptom pattern, the patients were contacted by the clinic to decide whether they had experienced an exacerbation and should have an extra visit within 24-48 hours. At an extra visit, nasal and throat swabs, induced sputum and blood were collected. Air pollution, temperature and humidity were also monitored daily. A subset of sub-group X, called sub-group M that consisted of 52 COPD patients and 15 healthy controls was dedicated to measure muscle strength and a dexa scan.
RESULTS: More than 78% of the enrolled patients completed the study successfully. There appeared a difference between the patient groups and the controls in gender, age, body mass index (BMI), forced expiratory volume in 1 second (FEV1), FEV1/FVC and smoking at baseline. In sub-group X 90 out of 203 (44.4%) selected COPD patients developed one or more exacerbations in the 2-year observation period. They were more severe COPD patients according to GOLD stage at study start. On average most exacerbations occurred in the month March and the least number of exacerbations occurred in October.
CONCLUSIONS: This study with the obtained patient dataset will allow a better insight in many aspects of exacerbations in COPD (e.g., the identification, the risk factors, phenotypes and the biomarkers).

Entities:  

Keywords:  China; Chronic obstructive pulmonary disease (COPD); demographics; exacerbations; study design

Year:  2015        PMID: 25973239      PMCID: PMC4419302          DOI: 10.3978/j.issn.2072-1439.2015.04.14

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  23 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

3.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  T A Seemungal; G C Donaldson; A Bhowmik; D J Jeffries; J A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

Review 4.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

5.  A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO.

Authors:  David M G Halpin; Tish Laing-Morton; Sarah Spedding; Mark L Levy; Peter Coyle; Jonathan Lewis; Paul Newbold; Penny Marno
Journal:  Prim Care Respir J       Date:  2011-09

6.  Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD.

Authors:  M C Steiner; R L Barton; S J Singh; M D L Morgan
Journal:  Eur Respir J       Date:  2002-04       Impact factor: 16.671

Review 7.  COPD exacerbations: the importance of a standard definition.

Authors:  R Pauwels; P Calverley; A S Buist; S Rennard; Y Fukuchi; E Stahl; C G Löfdahl
Journal:  Respir Med       Date:  2004-02       Impact factor: 3.415

8.  Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China.

Authors:  Shengming Liu; Yumin Zhou; Xiaoping Wang; Dali Wang; Jiachun Lu; Jingping Zheng; Nanshan Zhong; Pixin Ran
Journal:  Thorax       Date:  2007-05-04       Impact factor: 9.139

9.  Prevalence and risk factors of airflow obstruction in an elderly Chinese population.

Authors:  F W S Ko; J Woo; W Tam; C K W Lai; J Ngai; T Kwok; D S C Hui
Journal:  Eur Respir J       Date:  2008-08-06       Impact factor: 16.671

10.  An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study.

Authors:  Patrick Mallia; Simon D Message; Tatiana Kebadze; Hayley L Parker; Onn M Kon; Sebastian L Johnston
Journal:  Respir Res       Date:  2006-09-06
View more
  2 in total

1.  Erratum to Study on risk factors and phenotypes of acute exacerbations of chronic obstructive pulmonary disease in Guangzhou, China-design and baseline characteristics.

Authors: 
Journal:  J Thorac Dis       Date:  2015-07       Impact factor: 2.895

2.  The Expression of NOX4 in Smooth Muscles of Small Airway Correlates with the Disease Severity of COPD.

Authors:  Xianyan Liu; Binwei Hao; Ailing Ma; Jinxi He; Xiaoming Liu; Juan Chen
Journal:  Biomed Res Int       Date:  2016-08-30       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.